A81 POOLED SAFETY ANALYSIS FROM THE USTEKINUMAB CROHN’S DISEASE AND PSORIATIC DISEASES PHASE 2 AND 3 TRIALS

BACKGROUND: Ustekinumab (UST) is well-established in psoriasis (PsO) & psoriatic arthritis (PsA) with up to 5 years safety data from psoriasis clinical trials with 3117 pts & 8998 patient years (PY). However, limited safety data have been presented in Crohn’s disease (CD). In CD, Phase 2/3 d...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Can Assoc Gastroenterol
Hoofdauteurs: Feagan, B G, Sands, B E, de Villiers, W, Ott, E, Gasink, C, Lang, Y, Szapary, P, Jacobstein, D, Ghosh, S
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Oxford University Press 2018
Onderwerpen:
Poster Presentations
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6507608/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwy008.082
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items